An ethical conundrum – off-label prescribing of diabetes medications

You will learn:

• To gain insight into the ethical considerations of off-label prescribing and allocation of scarce resources
• To consider the ethical dilemma presented by patients who desire weight loss with off-label use of low-dose semaglutide (0.25mg, 0.5mg and 1mg), not registered for weight loss
• To understand the ADA/EASD consensus recommendations for a holistic, individualised approach to the management of type 2 diabetes and the ethical role of the physician in not diverting GLP-1 RA therapy away from high-risk patients
• An awareness of registered indications for the use of these dosages of semaglutide, and an understanding of the potential maleficence of off-label prescribing of semaglutide
• An ethical approach to the treatment of obesity for the patient who is not diabetic